ZA9896B - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists

Info

Publication number
ZA9896B
ZA9896B ZA9896A ZA9896A ZA9896B ZA 9896 B ZA9896 B ZA 9896B ZA 9896 A ZA9896 A ZA 9896A ZA 9896 A ZA9896 A ZA 9896A ZA 9896 B ZA9896 B ZA 9896B
Authority
ZA
South Africa
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
ZA9896A
Other languages
English (en)
Inventor
William H Miller
William E Bondinell
Thomas Wen Fu Ku
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA9896B publication Critical patent/ZA9896B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9896A 1997-01-08 1998-01-07 Vitronectin receptor antagonists ZA9896B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08

Publications (1)

Publication Number Publication Date
ZA9896B true ZA9896B (en) 1998-10-14

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9896A ZA9896B (en) 1997-01-08 1998-01-07 Vitronectin receptor antagonists

Country Status (30)

Country Link
US (2) US6069158A (de)
EP (1) EP0977735B1 (de)
JP (1) JP2001508067A (de)
KR (1) KR20000069941A (de)
CN (1) CN1249745A (de)
AP (1) AP9901597A0 (de)
AR (1) AR010873A1 (de)
AT (1) ATE235467T1 (de)
AU (1) AU729641B2 (de)
BG (1) BG103548A (de)
BR (1) BR9806852A (de)
CA (1) CA2276738A1 (de)
CO (1) CO4920232A1 (de)
DE (1) DE69812602T2 (de)
DZ (1) DZ2395A1 (de)
EA (1) EA199900630A1 (de)
ES (1) ES2196534T3 (de)
HU (1) HUP0001945A3 (de)
ID (1) ID23168A (de)
IL (1) IL130760A0 (de)
MA (1) MA26462A1 (de)
NO (1) NO993350L (de)
NZ (1) NZ336560A (de)
OA (1) OA11076A (de)
PE (1) PE44799A1 (de)
PL (1) PL334499A1 (de)
SK (1) SK92799A3 (de)
TR (1) TR199901575T2 (de)
WO (1) WO1998030542A1 (de)
ZA (1) ZA9896B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304117A1 (en) * 1997-09-04 1999-03-11 Dirk A. Heerding Integrin receptor antagonists
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
CN1140511C (zh) 1998-04-09 2004-03-03 明治制果株式会社 作为整合素αvβ3拮抗剂的氨基哌啶衍生物
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
JP2002536370A (ja) 1999-02-03 2002-10-29 メルク エンド カムパニー インコーポレーテッド α−Vインテグリン受容体拮抗薬としてのベンゾアゼピン誘導体
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
WO2001010844A1 (en) 1999-08-05 2001-02-15 Meiji Seika Kaisha, Ltd. φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6943156B2 (en) 2000-10-24 2005-09-13 Merck & Co., Inc Dibenzoxazepine αv integrin receptor antagonist
EP2292251A1 (de) 2001-04-24 2011-03-09 Merck Patent GmbH Kombinationstherapie mit Anti-angiogenen Mitteln und TNF-alpha
EP1443963B1 (de) 2001-10-22 2014-05-21 The Scripps Research Institute Antikörper-targeting-verbindungen
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
RS52918B (en) * 2004-04-02 2014-02-28 The Regents Of The University Of California PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US8282943B2 (en) 2005-05-31 2012-10-09 Ralf Jochem Therapeutic composition for use in the prevention and treatment of bone metastases
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
PT2101805E (pt) 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
EP0906103A1 (de) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Vitronectinrezeptor-antagonisten
JP2002510328A (ja) * 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina

Also Published As

Publication number Publication date
KR20000069941A (ko) 2000-11-25
OA11076A (en) 2003-03-13
EP0977735A1 (de) 2000-02-09
CO4920232A1 (es) 2000-05-29
TR199901575T2 (xx) 1999-11-22
SK92799A3 (en) 1999-12-10
MA26462A1 (fr) 2004-12-20
DE69812602D1 (de) 2003-04-30
IL130760A0 (en) 2001-01-28
EP0977735A4 (de) 2000-04-05
DZ2395A1 (fr) 2003-06-04
AP9901597A0 (en) 1999-09-30
WO1998030542A1 (en) 1998-07-16
NO993350L (no) 1999-09-06
BG103548A (en) 2000-11-30
ID23168A (id) 2000-03-23
DE69812602T2 (de) 2004-02-19
AR010873A1 (es) 2000-07-12
NZ336560A (en) 2000-11-24
US6191304B1 (en) 2001-02-20
CN1249745A (zh) 2000-04-05
CA2276738A1 (en) 1998-07-16
NO993350D0 (no) 1999-07-07
HUP0001945A3 (en) 2001-12-28
BR9806852A (pt) 2001-08-07
PE44799A1 (es) 1999-06-10
AU5912798A (en) 1998-08-03
ATE235467T1 (de) 2003-04-15
EP0977735B1 (de) 2003-03-26
US6069158A (en) 2000-05-30
AU729641B2 (en) 2001-02-08
JP2001508067A (ja) 2001-06-19
HUP0001945A2 (hu) 2000-10-28
PL334499A1 (en) 2000-02-28
ES2196534T3 (es) 2003-12-16
EA199900630A1 (ru) 2000-02-28

Similar Documents

Publication Publication Date Title
CY2576B1 (en) Vitronectin receptor antagonists
IL130760A0 (en) Vitronectin receptor antagonists
EP0767792A4 (de) Vitronectin-rezeptor antagonisten
ZA955391B (en) Vitronectin receptor antagonists
EP1000031A4 (de) Vitronectinrezeptor-antagonist
IL125030A0 (en) Vitronectin receptor antagonists
EP1047425A4 (de) Integrinrezeptor antagonisten
HUP9900754A3 (en) Vitronectin receptor antagonists
IL125034A0 (en) Vitronectin receptor antagonists
EP1007051A4 (de) Integrin rezeptor antagonisten
IL135028A0 (en) Vitronectin receptor antagonists
IL135189A0 (en) Vitronectin receptor antagonist
IL138245A0 (en) Vitronectin receptor antagonists
IL135188A0 (en) Vitronectin receptor antagonist
EP1027337A4 (de) Integrin-rezeptor-antagonisten
IL141163A0 (en) Vitronectin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
SI0957917T1 (sl) Antagonisti receptorja vitronektina
GB9822331D0 (en) Vitronectin receptor antagonists
GB9810882D0 (en) Vitronectin receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists
GB9810892D0 (en) Vitronectin receptor antagonists
GB9807382D0 (en) Vitronectin receptor antagonists
GB9807384D0 (en) Vitronectin receptor antagonists
GB9810182D0 (en) Vitronectin receptor antagonists